


## Methacycline hydrochloride

<b>Cat. No.:</b>	HY-B0449
<b>CAS No.:</b>	3963-95-9
<b>Molecular Formula:</b>	C <sub>22</sub> H <sub>23</sub> ClN <sub>2</sub> O <sub>8</sub>
<b>Molecular Weight:</b>	478.88
<b>Target:</b>	Bacterial; Antibiotic
<b>Pathway:</b>	Anti-infection
<b>Storage:</b>	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



HCl

### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 50 mg/mL (104.41 mM; Need ultrasonic)					
	H <sub>2</sub> O : 6.67 mg/mL (13.93 mM; Need ultrasonic)					
	<b>Preparing Stock Solutions</b>	<b>Solvent</b>	<b>Mass</b>	<b>1 mg</b>	<b>5 mg</b>	<b>10 mg</b>
		<b>Concentration</b>				
		<b>1 mM</b>		2.0882 mL	10.4410 mL	20.8821 mL
<b>5 mM</b>			0.4176 mL	2.0882 mL	4.1764 mL	
	<b>10 mM</b>		0.2088 mL	1.0441 mL	2.0882 mL	
Please refer to the solubility information to select the appropriate solvent.						
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.22 mM); Clear solution					

### BIOLOGICAL ACTIVITY

<b>Description</b>	Methacycline hydrochloride is a tetracycline antibiotic and can inhibit bacterial protein synthesis. Methacycline hydrochloride is a potent epithelial-mesenchymal transition (EMT) inhibitor. Methacycline hydrochloride blocks EMT in vitro and fibrogenesis in vivo without directly affecting TGF-β1 Smad signaling. Methacycline hydrochloride is an antimicrobial and has the potential for pulmonary fibrosis <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	Tetracycline
<b>In Vitro</b>	Methacycline hydrochloride is an inhibitor of A549 EMT with an IC <sub>50</sub> of roughly 5 μM <sup>[1]</sup> . In vitro, Methacycline hydrochloride (10, 20 μM; for 48 hours) inhibits TGF-β1-induced α-smooth muscle actin, Snail1, and collagen I of primary alveolar epithelial cells. Methacycline hydrochloride inhibits TGF-β1-induced non-Smad pathways, including c-Jun N-terminal kinase, p38, and Akt activation, but not Smad or β-catenin transcriptional activity. Methacycline has no effect on baseline c-Jun N-terminal kinase, p38, or Akt activities or lung fibroblast responses to TGF-β1 <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### In Vivo

In vivo, Methacycline hydrochloride (100 mg/kg/day; ip; beginning 10 days after intratracheal Bleomycin) improves survival at Day 17. Bleomycin-induced canonical EMT markers, Snail1, Twist1, collagen I, as well as fibronectin protein and mRNA, ARE attenuated by Methacycline hydrochloride (Day 17)<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### CUSTOMER VALIDATION

- EBioMedicine. 2022 Apr;78:103943.
- SLAS Discov. 2020 Sep;25(8):895-905.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

#### REFERENCES

[1]. Ying Xi, et al. Inhibition of epithelial-to-mesenchymal transition and pulmonary fibrosis by methacycline. Am J Respir Cell Mol Biol. 2014 Jan;50(1):51-60.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA